This review looked at data from 17 different studies involving 584 animals. The researchers focused on how a medication called empagliflozin affects metabolic dysfunction-associated steatotic liver disease (MASLD). This condition involves an accumulation of fat in the liver.
The findings showed that empagliflozin significantly reduced markers of liver fat, such as triglycerides and cholesterol. It also lowered signs of liver scarring, known as fibrosis, and decreased markers for inflammation and oxidative stress. Additionally, the medication improved blood sugar levels and insulin sensitivity in the animal models tested.
It is important to note that these results come from preclinical studies using animals, not from clinical trials in humans. Because this research was conducted in a laboratory setting, it does not yet prove how the drug will work for people. These findings are early and suggest a potential path for future treatments, but more human testing is needed.
